Division of Cardiology, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Unit of Interventional Cardiology, Department of Cardiothoracic Surgery, UPMC IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Palermo, Italy.
Eur Heart J. 2024 Nov 7;45(41):4399-4413. doi: 10.1093/eurheartj/ehae502.
The prevalence and mortality related to end-stage liver disease (ESLD) continue to rise globally. Liver transplant (LT) recipients continue to be older and have inherently more comorbidities. Among these, cardiac disease is one of the three main causes of morbidity and mortality after LT. Several reasons exist including the high prevalence of associated risk factors, which can also be attributed to the rise in the proportion of patients undergoing LT for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, as people age, the prevalence of now treatable cardiac conditions, including coronary artery disease (CAD), cardiomyopathies, significant valvular heart disease, pulmonary hypertension, and arrhythmias rises, making the need to treat these conditions critical to optimize outcomes. There is an emerging body of literature regarding CAD screening in patients with ESLD, however, there is a paucity of strong evidence to support the guidance regarding the management of cardiac conditions in the pre-LT and perioperative settings. This has resulted in significant variations in assessment strategies and clinical management of cardiac disease in LT candidates between transplant centres, which impacts LT candidacy based on a transplant centre's risk tolerance and comfort level for caring for patients with concomitant cardiac disease. Performing a comprehensive assessment and understanding the potential approaches to the management of ESLD patients with cardiac conditions may increase the acceptance of patients, who appear too complex, but rather require extra evaluation and may be reasonable candidates for LT. The unique physiology of ESLD can profoundly influence preoperative assessment, perioperative management, and outcomes associated with underlying cardiac pathology, and requires a thoughtful multidisciplinary approach. The strategies proposed in this manuscript attempt to review the latest expert experience and opinions and provide guidance to practicing clinicians who assess and treat patients being considered for LT. These topics also highlight the gaps that exist in the comprehensive care of LT patients and the need for future investigations in this field.
终末期肝病(ESLD)的患病率和死亡率在全球范围内持续上升。肝移植(LT)受者的年龄继续增大,固有合并症更多。其中,心脏病是 LT 后发病率和死亡率的三个主要原因之一。存在多种原因,包括相关危险因素的高发率,这也可归因于因代谢功能障碍相关脂肪性肝炎(MASH)而行 LT 的患者比例增加。此外,随着人们年龄的增长,现在可治疗的心脏疾病的患病率上升,包括冠心病(CAD)、心肌病、严重的瓣膜性心脏病、肺动脉高压和心律失常,因此需要治疗这些疾病以优化结果。关于 ESLD 患者的 CAD 筛查,有大量的文献,但缺乏强有力的证据来支持 LT 前和围手术期管理心脏疾病的指南。这导致 LT 候选者之间的移植中心在心脏疾病评估策略和临床管理方面存在显著差异,这基于移植中心对伴有心脏疾病的患者的风险容忍度和护理舒适度。进行全面评估并了解管理 ESLD 合并心脏疾病患者的潜在方法可能会增加患者的接受度,这些患者看似过于复杂,但需要额外的评估,并且可能是 LT 的合理候选者。ESLD 的独特生理学可以深刻影响术前评估、围手术期管理和潜在心脏病理学相关的结果,并且需要深思熟虑的多学科方法。本文提出的策略旨在回顾最新的专家经验和意见,并为评估和治疗考虑 LT 的患者的临床医生提供指导。这些主题还突出了 LT 患者综合护理方面存在的差距以及该领域未来调查的必要性。